MedTrace Logo

A Study of the Intratumoral Microdose Administration of PBA-0405 in Patients With Solid Tumors

NCT06273852 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2025-08-11

No results posted yet for this study

Summary

This is a multi-center, single arm, open-label, localized pharmacodynamic biomarker Phase 0 trial designed to study the biological effects within the tumor microenvironment of PBA-0405 when administered intratumorally in microdose quantities via the CIVO device.

Conditions

Interventions

DRUG

PBA-0405

Intratumoral microdose injection by the CIVO device.

Sponsors & Collaborators

  • Presage Biosciences

    collaborator INDUSTRY

  • Pure Biologics S.A.

    lead INDUSTRY

Principal Investigators

  • John Weinberg · Pure Biologics

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-04-29
Primary Completion
2025-03-15
Completion
2025-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06273852 on ClinicalTrials.gov